Mesoblast Ltd (MSB.AX) Key Developments | Reuters.com
Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.03AUD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,225,017
52-wk High
$4.06
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Mesoblast provides update on global heart failure program
Monday, 13 Jun 2016 06:55pm EDT 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

Mesoblast says co received $6.2 mln from Australian government for R&D
Thursday, 19 May 2016 07:55pm EDT 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

Mesoblast Ltd announces pricing of public offering on Nasdaq
Friday, 13 Nov 2015 08:39am EST 

Mesoblast Ltd:Says initial public offering of 7.5 million ads priced at $8.00/ADS.  Full Article

Celgene and Mesoblast extend agreement
Thursday, 15 Oct 2015 07:50pm EDT 

Mesoblast:Says it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal.Agreement with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.  Full Article

Mesoblast Limited announces positive trial results of mesoblast cell therapy in patients with diabetes and advanced chronic kidney disease
Monday, 8 Jun 2015 06:38pm EDT 

Mesoblast Limited:Announces that results from the company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe.Says it reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.  Full Article

Thorney Opportunities Ltd becomes initial substantial holder of Mesoblast Limited
Friday, 17 Apr 2015 03:00am EDT 

Mesoblast Limited:Says that Thorney Opportunities Ltd becomes initial substantial holder of the company effective April 14 with 18,851,000 ordinary shares and 5.81 pct voting power.  Full Article

Mesoblast Ltd and Celgene Corp enter into equity placement and right of first refusal agreement to certain disease fields
Sunday, 12 Apr 2015 08:00pm EDT 

Mesoblast Ltd:Enters into agreement with Celgene Corp, a global biopharmaceutical company engaged in development and commercialization of therapies for treatment of cancer and immune-inflammatory related diseases.Pursuant to this agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.Under terms of agreement, Celgene will purchase 15.3 million ordinary shares in Mesoblast Limited for a consideration of A$58.5 million/$45 million at a price of A$3.82 per share.In addition, Celgene has six-month right of first refusal with respect to Mesoblast's mesenchymal lineage adult stem cell product candidates for prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.  Full Article

Mesoblast Ltd's key patent allowed in Japan for treatment of heart diseases, stroke, and other vascular conditions
Thursday, 26 Mar 2015 06:45pm EDT 

Mesoblast Ltd:Announced that Japanese Patent Office has allowed key patent covering use of the company's proprietary adult Mesenchymal Precursor Cells (MPCs) for formation and repair of blood vessels in ischemic tissues.Japanese patent 2006-503990, entitled ‘Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation’, covers use of these cells derived from bone marrow, adipose tissue and dental pulp.Says that this patent provides commercial rights in Japan through to at least March 29, 2024, with potential for patent term extension for up to five years based on duration of clinical development.  Full Article

Mesoblast Ltd reports positive 24 month results in phase 2 trial for Chronic low back pain and initiation of phase 3 program
Wednesday, 14 Jan 2015 06:13pm EST 

Mesoblast Ltd:Says that it has presented positive 24-month results from its Phase 2 program for chronic low back pain.Additionally, announced that its Phase 3 program for this indication has been initiated.Mesoblast presented anticipated timelines for this Phase 3 program and noted that enrollment completion is expected in mid-2016, an interim analysis is expected in mid-2016 and top-line data are expected in mid-2017.The objective of the Phase 3 clinical program will be to confirm the positive outcomes from the Company's Phase 2 clinical trial.The primary endpoint will seek to confirm the treatment success seen in Phase 2 for MPC-06-ID against a control injection of saline.  Full Article

Mesoblast Ltd appoints Joins Mesoblast as chief financial officer
Sunday, 24 Aug 2014 09:30pm EDT 

Mesoblast Ltd:Announces appointment of Paul Hodgkinson as Mesoblast Chief Financial Officer.  Full Article